In a report released yesterday, Brian Skorney from Robert W. Baird maintained a Buy rating on Immunovant (IMVT), with a price target of $20.00. The company’s shares closed last Tuesday at $9.40, close to its 52-week low of $9.22.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 5.0% and a 51.7% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.
Immunovant has an analyst consensus of Moderate Buy, with a price target consensus of $22.00, which is a 93.7% upside from current levels. In a report released yesterday, Truist Financial also maintained a Buy rating on the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
Based on Immunovant’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $31.78 million. In comparison, last year the company had a GAAP net loss of $11.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
